NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The market is currently shaping up for an interesting week, with the Trumpcare bill still casting its shadow on the industry. The share prices of the industry's best players are all on an upward trend, with Arena Pharmaceuticals and Immunomedics experiencing a 2.05% and 1.02% rise in their stock price. Arena's weight loss drug was approved last week, while Immunomedics enjoyed maximum technical strength. Let's take a closer look at today's numbers.

RDI Initiates Coverage:

Arena Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ARNA

Immunomedics, Inc.
https://ub.rdinvesting.com/news/?ticker=IMMU

Arena Pharmaceuticals' investors breathe a sigh of relief with the company now experiencing positive results with regard to its share value. The company's shares are now selling at $1.49, representing a 2.05% increase.

The company's trading volume is way below the average 3.79 million shares, with the company today selling 1.19 million worth of shares. Experts had predicted an increase, to soar above last year's $2.16 52 week high. The company, however, is likely to receive backlash due to the speed at which the share price is increasing. The company's EPS currently stands at 0.26. Analysts seem to have underestimated the company's earnings per share, who predicted a negative EPS value. With a market capitalization of $359.61 million, the company is doing better compared to other players in the industry.

Access RDI's Arena Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=ARNA

Immunimedics started the day on a high, with the share price slowly curling north as the day progressed. The share price currently stands at $6.95, representing a 1.02% rise from the previous day's $6.88 closing value. This increase might not seem as much, but the company is currently enjoying an impressive bull rating, which is achieving extreme strength through technical resistance.

The share price has been moving up rapidly, and the resistance is showing. Its stock performance has gained 148% over the past year, with the last trading session involving 2.6 million worth of share volume. The company's current market capitalization stands at 100.6 million, with a volatility rate of 12.7%.

Access RDI's Immunomedics Research Report at: https://ub.rdinvesting.com/news/?ticker=IMMU

Our Actionable Research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Immunomedics, Inc. (NASDAQ: IMMU) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com